ANAHEIM, Calif.—Ozarelix, a GnRH antagonist given intramuscularly, is well tolerated and has significant and clinically meaningful efficacy in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH, a study shows.

FOR 30 years, lasers have been evolving for the treatment of urologic conditions. Investigators focused on lasers for BPH to achieve results similar to transurethral resection of the prostate (TURP) without the bleeding, fluid overload, blood loss, inpatient hospital stays of two to three days, and erectile dysfunction associated with TURP.

ANAHEIM, Calif.—Moderate to severe lower urinary tract symptoms (LUTS) are present in 42% of men over age 50 who visit their primary-care physician (PCP), according to data presented here at the American Urological Association annual meeting.

ANAHEIM, Calif.—Just one injection of botulinum toxin type A (Botox) into the prostate may provide relief from BPH-related lower urinary tract symptoms (LUTS) for up to 12 months.

A study of Swedish men with BPH found no excess risk of bladder cancer, but did show that the likelihood of the malignancy is elevated in those who undergo transurethral resection of the prostate (TURP), especially men with comorbid genitourinary tract conditions.

Botulinum toxin type A (BTX-A) injections may be a promising treatment for BPH patients with urinary retention who are not candidates for surgery.

Photoselective vaporization of the prostate (PVP) for BPH provides outcomes similar to those of transurethral resection of the prostate (TURP).

Men who take finasteride or alpha blockers for BPH are at higher risk of prostate cancer than non-users, investigators in Finland conclude.

Intravesical prostatic protrusion (IPP) is a useful predictor of outcomes in patients with BPH, studies show.

AS LITTLE AS 1 mg/day of finasteride can seriously distort the results of a PSA screening for prostate cancer, a recent study has found.